Podcasts about SITC

Hey everyone, welcome back! Can we just take a moment to appreciate the adorableness of our sister telepathy? We literally showed up dressed the exact same today—first time ever in SITC history, and it was totally unplanned!

SITC is back in the studio with this long-awaited episode covering the softcore juggernaut that is the Emmanuelle film franchise!  Expert Bryan Connolly joins Torie to dissect this smutty phenomenon which is SO expansive and SO diverse, it's basically an ecosystem. From Thailand to Africa, to Outer Space, Emmanuelle knows no bounds. In the original EMMANUELLE (1974) starring Sylvia Kristel, we watch Emmanuelle the girl become Emmanuelle the woman thanks to a few trips to the Mile High Club and guidance from a mansplaining creep named Mario. We take a detour outside of official Emmanuelle "canon" with EMANUELLE AND THE WHITE SLAVE TRADE (1978), one of the many (and one of the best) ripoffs that make up the multifaceted Emmanuelle universe. Starring Laura Gemser, Emanuelle with One M is a slick and ambitious journalist with the savvy and sexual appetite to rival James Bond. We conclude our journey with the first installment of Emmanuelle's Skinemax/ straight-to-video era, EMMANUELLE: FIRST CONTACT (1994). Starring Krista Allen, Emmanuelle takes her sage-like knowledge of sex to outer space where she educates hunky alien Halfron and his brethren about the joys and politics of human sexuality.    — Bryan Connolly is a writer and filmmaker in Austin, TX. Thanks to a lifelong obsession with the Emmanuelle films, his encyclopedic knowledge has cemented him as a de-facto Emmanuelle expert. Bryan has contributed to Severin Films' Black Emanuelle Box Set, the Emmanuelle comic book series from Fantagraphics, and is currently writing a colossal tome covering every Emmanuelle movie ever made. Bryan's cinema expertise also extends well beyond the boundaries of Emmanuelle. He is the co-host of the podcast The Directors Wall alongside A.J. Gonzalez, the author of Destroy All Movies: The Complete History of Punks on Film, a feature filmmaker, and much more.  LINKS! Listen to The Directors Wall podcast here! Check out Bryan's feature film MAKE POPULAR MOVIES free on Tubi here! Snag a copy of Bryan's book Destroy All Movies: The Complete History of Punks on Film on eBay for a mint here!

Awards season is here is SITC is kicking off 2025 with our inaugural *AFTERGLOW AWARDS*!! With winners selected from the pool of every film covered on SITC to date, all winners of these prestigious awards have been carefully chosen by an esteemed panel of two (aka us). We also go into some long tangents around NOSFERATU, THE BRUTALIST, and movie theater hot dogs.   Check out the categories below and tune in to reveal the winners of ! - Best Sex Scene in a Motion Picture Hottest Actor in a Motion Picture Hottest Actress in a Motion Picture Hottest Couple in a Motion Picture Best Unconventionally Hot Sex Scene in a Motion Picture Best WTF Unsexy Scene in a Motion Picture Best Masturbation in a Motion Picture Best Full Frontal in a Motion Picture Best Orgasm in a Motion Picture Sexiest Sound in a Motion Picture

JCO PO author Dr. David R. Gandara at UC Davis Comprehensive Cancer Center, shares insights into his JCO PO article, “Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer,” one of the Top Articles of 2024. Host Dr. Rafeh Naqash and Dr. Gandara discuss how the PROphet® blood test supports first-line immunotherapy treatment decisions for metastatic NSCLC patients. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today, we are absolutely thrilled to be joined by Dr. David R. Gandara, Professor of Medicine Emeritus, Co-Director of the Center for Experimental Therapeutics and Cancer and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center and also the senior author of the JCO Precision Oncology article entitled “Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer.” This was one of the top performing articles of 2024, which is one of the reasons why we wanted to bring it in for a podcast discussion. At the time of this recording, our guest's disclosures will be linked in the transcript.  David, it is an absolute pleasure to have you today. For somebody like you who's led the field of lung cancer over the years, I'm really excited that you are going to be talking to us about this very interesting article, especially given that I think you're one of the big proponents of liquid biopsies and plasma-based testing. So, for the sake of our listeners - which comprises of academic oncologists, community oncologists, trainees - could you tell us where the biomarker landscape for non-small cell lung cancer is currently, and then we can try to take a deeper dive into this article. Dr. David Gandar: Okay. Well, thank you, Rafeh. It's a pleasure to be with you here today. And I think the current landscape for biomarkers for immunotherapy in non-small cell lung cancer is a mess. There's no better way to describe it. That makes this paper describing a new plasma proteomic assay even more important. So I'll just give you a perspective. There are 14 trials, phase three trials, that were done in first line non-small cell lung cancer advanced stage of immunotherapy versus chemotherapy and some other aspects, although they vary tremendously. Some of them were checkpoint monotherapy, some combined with chemotherapy, some combined with CTLA-4 inhibitors and so forth. 12 out of the 14 were positive, 12 got FDA approval. So there are 12 different options that an oncologist could use. Some of them were squamous cell only, some non-squamous, some used PD-L1 as a biomarker driven part of the study. Some used TMB, tumor mutational burden, some were agnostic. So when you put all of this together, an oncologist can pick and choose among all these various regimens. And by and large, it's PD-L1 that is the therapeutic decision maker.  ASCO actually, I think, has done the very best job of making a guideline, and it's, as you well know, called a living guideline, it's dynamic. And it is much easier to interpret, for me and I think for oncologists, than some of the other guidelines. It's got a green light and a red light, it may be kind of orange. And so the green light means this is a strong recommendation by the guideline committee. The orange means it's weak. For this purpose, non-small cell lung cancer, advanced stage, only a very few of the recommendations were green. It's mainly monotherapy and patients with cancers with a PD-L1 over 50%. In our surveys, at our meetings, less than 50% of oncologists in the United States are following these guidelines. Why? Because they don't trust the biomarker. And TMB has the same sort of limitations. They're not bad biomarkers, they're incomplete. They're only looking at a part of the story. So that means we need a new biomarker. And this is one that, I think, the data are quite impressive and we'll discuss it more. Dr. Rafeh Naqash: Absolutely. Like you said, abundance of many therapy options, but not necessarily everything works the same in different subsets of PD-L1 positivity or different subsets of patients with different levels of tumor burden. And like you said, again, difficulty in trying to identify the right biomarker. And that's a nice segue to this PROphet test that you guys ran. So can you tell us a little bit about the plasma proteomic assay? Because to the best of my knowledge, there's not a lot of validated plasma proteomic assays. A lot has been done on the tumor tissue side as far as biomarkers are concerned, but not much on the blood side, except for maybe ctDNA MRD testing. So what was the background for trying to develop a plasma-based proteomic test? And then how did this idea of testing it in the lung cancer setting come into play? And then we can go into the patient population specifics, the cohort that you guys have. Dr. David Gandara: Okay. Well, of course there's a company behind this assay, it's called OncoHost, and I'm a consultant for them. And they came to me two years ago and they said, “We have something different from anyone else.” And they explained the science to me, as well as some other lung cancer experts here in the United States. I'm not a proteomic expert, of course, but they developed an AI machine learning platform to assess plasma proteins in normal people and in people with cancer, and specifically then in people with non-small cell lung cancer. They identified over 7,000 proteins that had cancer implications for therapy, for resistance, for prognosis, etc., and they categorized them based on the literature, TCGA data, etc., and used this machine learning process to figure out which proteins might be most specific for non-small cell lung cancer. And that's where they started. And so out of that 7,000 proteins, where they've identified which ones are angiogenic, which ones are involved with EMT or cell cycle or whatever it might be, they distilled it down to 388 proteins which they thought were worth testing in non-small cell lung cancer. And that's when I became involved.  They had a retrospective cohort of patients that had been treated with various immunotherapies. They looked at the analytic validation first, then applied it to this cohort. It looked good. Then they had a very large cohort, which they split, as you usually do with an assay, into a test set and then a validation set. For the test set, they wanted something more than a response. They wanted some indicator of long term benefit because that's where immunotherapy differentiates itself from chemotherapy and even targeted therapy. And so they picked PFS at 12 months. And I became involved at that point and it looked really good. I mean, if you look at the figures in the manuscript, the AUC is superb about their prediction and then what actually happened in the patient. And then in this paper, we applied it to a validation set of over 500 patients in a prospective trial, not randomized, it's called an observational trial. The investigator got to pick what they thought was the best therapy for that patient. And then in a blinded fashion, the proteomic assay experts did the analysis and applied it to the group.  And so what that means is some of the patients got chemotherapy alone, some got checkpoint immunotherapy monotherapy, some got in combination with chemotherapy. None of the patients in this study got a CTLA-4 inhibitor. That work is ongoing now. But what the study showed was that this assay can be used together with PD-L1 as what I would call a composite biomarker. You take the two together and it informs the oncologist about the meaning of that PD-L1. I'll give you an example. If that patient has a PD-L1 over 50% in their cancer and yet the PROphet test is negative, meaning less than 5 - it's a 0 to 10 scale - that patient for survival is better served by getting chemotherapy and immunotherapy. However, if the PROphet test is positive and the PD-L1 is over 50%, then the survival curves really look equivalent. As I said earlier, even in that group of patients, a lot of oncologists are reluctant to give them monotherapy. So if you have a test and the same sort of example is true for PD-L1 0, that you can differentiate. So this can really help inform the oncologist about what direction to go. And of course then you use your clinical judgment, you look at what you think of as the aggressiveness of the tumor or their liver metastases, etc. So again, that's how this test is being used for non-small cell lung cancer. And maybe I'll stop there and then I'll come back and add some other points. Dr. Rafeh Naqash: I definitely like your analogy of this therapy de-escalation strategy. Like you mentioned for PD-L1 high where the PROphet test is negative, then perhaps you could just go with immunotherapy alone. In fact, interestingly enough, I was invited to a talk at SITC a couple of weeks back and this exact figure that you're referring to was one of the figures in my slide deck. And it happened by chance that I realized that we were doing a podcast on the same paper today.  So I guess from a provocative question standpoint, when you look at the PD-L1 high cohort in the subset where you didn't see a survival difference for chemo plus immunotherapy versus immunotherapy alone, do you think any element of that could have been influenced by the degree of PD-L1 positivity above 50%? Meaning could there have been a cohort that is, let's say PD-L1 75 and above, and that kind of skews the data because I know you've published on this yourself also where the higher the PD-L1 above 50%, like 90% PD-L1 positivity survival curves are much better than 50% to 89%. So could that have somehow played a role? Dr. David Gandara: The first thing to say is that PD-L1 and the PROphet score, there's very little overlap. I know that sounds surprising, but it's also true for tumor mutational burden. There's very little overlap. They're measuring different things. The PD-L1 is measuring a specific regulatory protein that is applicable to some patients, but not all. That's why even in almost all of the studies, people with PD-L1 0 could still have some survival benefit. But in this case they're independent. And not in this paper, but in other work done by this group, the PROphet group, they've shown that the PROphet score does not seem to correlate with super high PD-L1. So it's not like the cemiplimab data where if you have a PD-L1 of greater than 90%, then of course the patient does spectacularly with monotherapy. The other thing that's important here is they had a group of around a little less than 100 patients that got chemotherapy alone. The PROphet score is agnostic to chemotherapy. And so that means that you're not just looking at some prognostic factor. It's actually clinical utility on a predictive basis. Dr. Rafeh Naqash: I think those are very important points. I was on a podcast a couple of days back. I think there's a theme these days we're trying to do for JCO Precision Oncology, we're trying to do a few biomarker based podcasts, and the most recent one that we did was using a tissue transcriptome with ctDNA MRD and you mentioned the composite of the PD-L1 and the PROphet test and they use a composite of the tissue transcriptome. I believe they called it the VIGex test as well as MRD ctDNA. And when your ctDNA was negative at, I believe, the three month mark, those individuals had the highest inflamed VIGex test or highest infiltration of T cells, STING pathway, etc. So are there any thoughts of trying to add or correlate tissue based biomarkers or ctDNA based correlations as a further validation in this research with the company? Dr. David Gandara: Right. So there are many things that are being looked at, various composites looking at the commutations that might affect the efficacy of immunotherapy and how they correlate with profit positivity or negativity. And I'll just give the examples of STK11 and KEAP1. As you know, there's some controversy about whether these are for immunotherapy, whether they're more prognostic or predictive. I'm one of the co-authors among many in the recently published Nature paper by Dr. Skoulidis and the group at MD Anderson which report that for KEAP1 positive especially, but also SDK11 mutated getting immunotherapy, that that's where the CTLA-4 inhibitors actually play the greatest role. So realizing that this is still controversial, there are preliminary data, not published yet, that'll be presented at an upcoming meeting, looking at many of these other aspects, P53, SCK11, KEAP1, other aspects, TMB, that's actually already published, I think in one of their papers. So yes, there's lots of opportunities.  The other cool thing is that this isn't a test, it's a platform. And so that means that the OncoHost scientists have already said, “What if we look at this test, the assay in a group of patients with small cell lung cancer?” And so I just presented this as a poster at the world conference in San Diego. And it turns out if you look at the biology of small cell, where neither PD-L1 nor TMB seem to be very important, if you look at the biology of small cell and you form an assay, it only shares 44 proteins out of the 388 with non-small cell. It's a different biology. And when we applied that to a group of patients with small cell lung cancer, again it had really pretty impressive results, although still a fairly small number of patients. So we have a big phase three study that we're doing with a pharmaceutical company developing immunotherapy where we are prospectively placing the PROphet test in a small cell trial.  The platform can also be altered for other cancer types. And at AACR, Dr. Jarushka Naidoo presented really impressive data that you can modify the proteins and you can predict immunotherapy side effects. So this is not like a company that says, “We have one test that's great for everything.” You know how some companies say, “Our test, you can use it for everything.” This company is saying we can alter the protein structures using AI machine learning assisted process to do it and we can have a very informed assay in different tumor types and different situations. So to me, it's really exciting. Dr. Rafeh Naqash: Definitely to me, I think, combining the AI machine learning aspect with the possibility of finding or trying to find a composite biomarker using less invasive approaches such as plasma or blood, definitely checks a lot of boxes. And as you mentioned, trying to get it to prospective trials as an integral biomarker perhaps would be likely the next step. And hopefully we see some interesting, exciting results where we can try to match or stratify patients into optimal combination therapies based on this test.  So now to the next aspect of this discussion, David, which I'm really excited about. You've been a leader and a mentor to many. You've led ISLC and several other corporate group organizations, et cetera. Can you tell us, for the sake of all the listeners, junior investigators, trainees, what being a mentor has meant for you? How your career has started many years back and how it's evolved? And what are some of the things that you want to tell people for a successful and a more exciting career as you've led over the years? Dr. David Gandara: Well, thank you for the question. Mentoring is a very important part of my own career. I didn't have an institutional mentor when I was a junior investigator, but I had a lot of senior collaborators, very famous people that kind of took me under their wing and guided me. And I thought when I basically establish myself, I want to give back by being a mentor to other people. And you wouldn't believe the number of people that I'm even mentoring today. And some of them are not medical oncologists, they're surgeons, they're radiation oncologists, they're basic scientists. Because you don't have to be an expert in that person's field to be a mentor. It helps, but in other words, you can guide somebody in what are the decision making processes in your career. When is it time to move from this institution onward because you can't grow in the institution you're in, either because it's too big or it's too small? So I established a leadership academy in the Southwest Oncology Group, SWOG. I've led many mentoring courses, for instance, for ISLC, now for International Society Liquid Biopsy, where I'm the executive committee liaison for what's called The Young Committee. So ISLB Society, totally devoted to liquid biopsy, six years old now, we have a Young Committee that has a budget. They develop projects, they publish articles on their own, they do podcasts. So what I'm saying is those are all things that I think opens up opportunities. They're not waiting behind senior people, they are leading themselves.  We just, at our International Lung Cancer Congress, reestablished a fellows program where a group of fellows are invited to that Huntington beach meeting. It's now in its 25th year and we spend a day and a half with them, mentoring them on career building. I'll just give you my first, I have the “Letterman Top 10”. So my first recommendation is if all you have is lemons, make lemonade. And what I'm meaning is find what you can do at your institution if you're a junior person, what you can claim to be your own and make the very best of it. But then as you get further along in my recommendations, one of them is learn when to say ‘no'. Because as a junior investigator the biggest threat to your career is saying ‘yes' to everybody and then you become overwhelmed and you can't concentrate. So I'll stop there. But anyway, yes, mentoring is a big part of my life. Dr. Rafeh Naqash: Well, thank you, David. This is definitely something that I'm going to try to apply to my career as well. And this has been an absolute pleasure, especially with all the insights that you provided, not just on the scientific side but also on the personal career side and the mentorship side. And hopefully we'll see more of this work that you and other investigators have led and collaborated on. perhaps more interesting plasma based biomarkers. And hopefully some of that work will find its home in JCO Precision Oncology. Thank you again for joining us today. Dr. David Gandara: My pleasure. Dr. Rafeh Naqash: And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service organization, activity or therapy should not be construed as an ASCO endorsement.   Dr. David Gandara Disclosures: Consulting or Advisory Role Company: Henlius USA, Foundation Medicine, Janssen Pharma, Merck & Co, Mirati Therapeutics, Regeneron, AstraZeneca, Guardant Health, Genentech, Exact Sciences  Research Funding Company: Amgen, Genentech, Astex Pharma  

INE pone restricciones para los candidatos de cara a la elección judicial  El programa Bachetón se mantendrá vigente en los 31 estados en todo el país: SICT   Condonan deuda a 150 mil personas que tienen con las universidades de EEUU: Biden  Más información en nuestro podcast

JCO PO authors Dr. Philippe Bedard (Staff Medical Oncologist at Princess Margaret Cancer Centre and Professor of Medicine at University of Toronto) and Dr. Alberto Hernando Calvo (Medical Oncologist at Vall d´Hebron University Hospital) share insights into their JCO PO article, “Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab,” one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Drs. Bedard and Hernando Calvo discuss how combined transcriptome and ctDNA longitudinal analysis associates with pembrolizumab outcomes. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today we are excited to be joined by Dr. Philippe Bedard, Staff Medical Oncologist at the Princess Margaret Cancer Center and Professor of Medicine at the University of Toronto, as well as by Dr. Alberto Hernando-Calvo, Medical Oncologist at the Vall d'Hebron University Hospital, both authors of the JCO Precision Oncology article titled, “Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.”  Thank you for joining us today. Phil and Alberto. Dr. Alberto Hernando-Calvo: Thank you. Dr. Philippe Bedard: Great to be with you. Thanks for having us.  Dr. Rafeh Naqash: One of the reasons we do this podcast, as some of the listeners who listen to this podcast regularly may know, is to bring in novel approaches and try to understand how the field is moving towards a space where we are understanding biomarkers better. So your manuscript that was published in JCO Precision Oncology fulfills many of those criteria. And interestingly enough, I was at a conference at the Society for Immunotherapy of Cancer last month earlier in November and a lot of excitement at SITC was revolving around novel transcriptomic biomarkers, proteomic biomarkers or imaging based biomarkers. So could you tell us a little bit about why you started looking at biomarkers? This is an extremely competitive field. Why did you think that looking at the transcriptome is somewhat different from or more interesting from tumor mutational burden PDL-1 than other biomarkers that we currently use? And that question is for you Alberto to start off.  Dr. Alberto Hernando-Calvo: So I think gene expression profiles may have a predictive performance as compared to already existing biomarkers and this was one of the points that we describe in our manuscript. The gene expression signature that we developed back in 2019 at Vall d'Hebron Institute of Oncology was initially developed based on over 45 different tumor types and tested in over 1000 patients treated with antiPD-1 and anti PDL-1. And back then and in this manuscript, we proved that for instance the gene expression signature VIGex that we developed has a potential complementary role to other predictive biomarkers. In this case, we observe this predictive power with ctDNA dynamics and we then see a correlation with other existing biomarkers such as tumor mutational burden. So I don't think we need to use one or the other, but rather they may have additive predictive power. So we need to better individualize predictive biomarkers based on tumor types and select the best combination possible to improve the performance.  Dr. Rafeh Naqash: I completely agree that one size does not fit all, especially in the landscape of immunotherapy. From your perspective, when you developed the original signature, how did you choose what genes to look at? I looked at the manuscript, on the methodology side, some of the signatures are pro-inflammatory STING interferon gamma based, so how did you try to identify that these are the 7 to 10 or whatever number of signatures on the transcriptome side? And then why did you try to combine it with ctDNA based changes?  Dr. Alberto Hernando-Calvo: Back in our initial manuscript, published in Med from Cell Press, we developed the VIGex gene expression signature, as I mentioned, with taking into consideration over 1000 tumor samples from FFPE that we can consider real world samples because they are from real patients coming from the clinic notes as part of real investigational protocol doing or performing biopsies on patients. We did observe after doing a VIGex research and doing different tests, we eventually collected these 12 different genes. Because there is a combination of both genes involved in the interferon gamma pathway, we have genes associated with Tregs as well as T cell memory cells. So it's not only looking at genes that are associated with T cell activation or CD8+ T cell infiltration, but also looking at genes that may be overactivated, overexpressed, an immunosuppressive tumor microenvironment. So it was both selecting genes, the minimum number of genes to do it more scalable and having the minimum dataset of genes and including in the signature genes that are already at targets for immune sequent inhibitors or are being tested in immunotherapy combinations.  Dr. Rafeh Naqash: Thank you. And Phil, for the sake of our listeners, could you elaborate upon this aspect of using ctDNA? So this was tumor-informed ctDNA from what I understood in the manuscript. You guys basically try to use it to understand changes in the ctDNA with treatment and then try to combine it with the transcriptome signature. How did the idea come up initially and how did you plan on combining this with an RNA-based signature? Because I have seen manuscripts and other data where people are either using one or the other, but not necessarily both together. So how did you guys come up with that idea? Dr. Philippe Bedard: Well, we thought that this was a great opportunity to look at the combination of the transcriptome as well as the ctDNA dynamics because we had run an investigator-initiated phase 2 clinical trial called INSPIRE at our institution at Princess Margaret from 2016 to 2018, where patients across five different tumor groups received single agent pembrolizumab. And we really did a deep dive on these patients where there were tumor biopsies before and while on treatment. We did exome sequencing, we did RNA sequencing to capture the transcriptome. And in a prior analysis, we had partnered with Natera to look at their Signatera assay, which is a bespoke ctDNA assay, to look at ctDNA dynamics using this test and the association with response outcomes as well as survival outcomes. So we thought that this was a really unique data set to try and address the question of whether or not there was complementarity in terms of looking at the transcriptome and transcriptome signatures of IO benefit together with the ctDNA dynamics. Dr. Rafeh Naqash: From a patient treatment standpoint, it sounded like you mostly tried to include individuals who were treated with pembrolizumab. Did this not include individuals who were treated with chemoimmunotherapy or chemotherapy with pembrolizumab? Just pembrolizumab alone? And if that's the case, some of the tumor types there included, from what I remember, ovarian cancer and some other unusual cancers that don't necessarily have approvals for single agent pembrolizumab, but perhaps in the TMB-high setting. So can you elaborate on the patient selection there for the study?  Dr. Philippe Bedard: Yeah, that's a great question. So at the time that the study was designed in 2015, this was really the early days of immune checkpoint inhibitor therapy, so we didn't have the approvals that we have now in specific tumor types for immunotherapy and chemotherapy combinations. So when the study was designed as an investigator initiated clinical trial, the idea was really to capture patients across different tumor types - so head and neck squamous cell carcinoma, malignant melanoma, ovarian cancer, triple negative breast cancer, and a kind of mixed histology solid tumor cohort, where we knew that there were some patients who were going to be immunotherapy responsive, where there was already approvals or evidence of single agent activity, and others where the responses were more anecdotal, to try and understand in a phase 2 clinical trial with kind of a deep dive, which patients benefited from treatment and which didn't. Dr. Rafeh Naqash: Interesting approach. Going to the results, Alberto, could you help us understand some of the important findings from these data? Because there's different sections of how you tried to look at the response rates, the survival, looking at the immune deconvolution, if you could explain that. Dr. Alberto Hernando-Calvo: So the first thing that we tried was to further confirm the external validation of this immune gene expression signature, VIGex in the INSPIRE asset. So what we observed at VIGex-Hot, the category defined by VIGex-Hot tumor microenvironment, was associated with better progression free survival. After including that in a multivariable analysis adjusted by other biomarkers such as TMB, PDL-1 or tumor type, this was also confirmed for overall survival. So then the next step was to really try to hypothesize if the addition of ctDNA dynamics, taking into consideration the ctDNA quantification at baseline as compared to cycle three, if those dynamics could further improve the predictive performance of VIGex categories taken in the baseline samples. What we did observe was that, for instance, VIGex-Hot tumors in baseline tumor samples that were having a ctDNA decrease, as I mentioned before on cycle three assessment as compared to baseline, were having both better progression free survival and better prognosis overall. Another important finding was the evaluation of response rate across tumor types considering both biomarkers. I would say the most important finding is that when we were considering a cold tumor microenvironment in baseline samples before pembrolizumab initiation plus an increase in ctDNA values, what we observed is that those patients were having a 0% response rate. So this may help as a future strategy either for intensification of immunotherapy regimens in a more individualized way or for an early stop to immunotherapy and try to avoid financial toxicities as well as toxicities for our patients. Dr. Rafeh Naqash: From the data that you showed, it seems that there was a strong correlation, as you sort of mentioned, between individuals that had ctDNA clearance and baseline immune pro-inflammatory signatures. So do you really need the transcriptome signature or could the ctDNA just serve as an easy quick surrogate? Because from a cost standpoint, doing whole transcriptome sequencing or more RNA sequencing or tissue standpoint, where tissue is often limited, can become a big issue. So do you think that validation of this may perhaps more revolve around using ctDNA as an easier metric or surrogate? Or am I overestimating the utility of ctDNA? Dr. Philippe Bedard: I think it's a really good question. In our data set which was relatively small, there were 10 patients who had ctDNA clearance, meaning ctDNA that was positive at baseline was not detected. And so 9 out of those 10 patients, as you alluded to, were VIGex-Hot. So the question is a good one, could you do the same with just ctDNA clearance alone, particularly in identifying these patients who really do well, who have long term disease control on immunotherapy? I think it's a tough question to answer because the field is also changing in terms of sensitivity of detection of ctDNA tests. So we know now that there are newer generations of tests which can detect even at logs down in terms of allele variants in the circulation. So I think we need more data to address the question. I think it is important as to what is the best test, what is the endpoint that we should be using from a drug development point of view in terms of really trying to push and understand which treatment regimens are the most effective and have early readouts in terms of activity. Because we all recognize in the clinic that radiographic response doesn't tell the whole story, especially early radiographic assessments using RECIST or other criteria that we apply in clinical trials. Dr. Rafeh Naqash: From a clinical trial standpoint, we often talk about validation of these studies. You may have heard of other tests where, for example, the NCI iMatch, which is incorporating transcriptome sequencing based approach to stratify patients as an integral biomarker for treatment stratification. Is that something that you guys are thinking of using, this approach where individuals who are signature highly inflamed perhaps get lesser therapies or there's a de-intensification of some sort similar to what people are trying to do with ctDNA-based approaches? Dr. Philippe Bedard: I think that's a great question. I think it makes a lot of sense. And certainly, with the new wave antibody drug conjugates in terms of identifying patients who have expression of targets for antibody drug conjugates, that's very attractive as an approach because we don't necessarily have IHC markers for all of the different targets of antibody drug conjugates. We don't necessarily have IHC markers to completely understand different contributions to the tumor microenvironment and whether or not tumors are inflamed. But it's also a challenging approach too because RNA-seq currently is not a routine clinical test. Sometimes there are issues, particularly in patients who have stored specimens that are formalin-fixed and paraffin-embedded in terms of the quality of the RNA for RNA sequencing. And it's not always feasible to get pre-treatment biopsies and turn them around in an approach. So I think it is an attractive approach for clinical trials, but it's a hypothesis that needs to be tested. It's not something that is ready for clinical prime time today in 2024. Dr. Rafeh Naqash: One of the other interesting observations that I came across in your manuscript was that tumor mutational burden, interestingly, did not correlate with signature high tumors. What is the explanation for that? Because generally you would expect a TMB high to perhaps also have an immune gene high signature. Could it have something to do with the tumor types because there was a heterogeneous mixture of tumor type? Or I'm not sure. What else could you possibly think of that you didn't see those correlations or just sample size limitations? Dr. Alberto Hernando-Calvo: Yes. So our findings are consistent with prior data suggesting for instance T cell inflamed gene expression profile was also not correlated with tumor mutational burden and both biomarkers in a prior publication. So to have additive predictive performance for identifying patients most likely to benefit from anti PD-1 regimen, so we somehow were expecting this observation, the fact that both biomarkers are not very correlated. Dr. Rafeh Naqash: So given the proof of concept findings from your study, Phil, what is the next interesting step that you guys are thinking of to expand this? Would you think that a nivolumab-ipilimumab treated cohort would have similar findings? Or is this a treatment specific single agent immunotherapy specific correlation that you found versus something else that you may find in a nivo-ipi cohort or a doublet immune checkpoint cohort?  Dr. Philippe Bedard: The findings are really hypothesis generating. They require additional validation. And you're quite right, there may be nuances in terms of specific tumor types, combinations with other immunotherapy or combinations with chemotherapy or other agents. So I think it would be great if there are other data sets that are collecting this type of information that have ctDNA dynamics and also have transcriptome and potentially exome or genome analysis to look at these types of questions because the field is moving quickly and we really need more data sets in order to understand some of the nuances and greater numbers to validate the signals that we see. Dr. Rafeh Naqash: And one thing, as you said, the field is definitely moving very quickly. I was meeting with a company an hour back and they have an imaging-based approach using fresh tissue to look at pharmacodynamic biomarkers. And I used to work in the NCI with a group that was very interested and they developed an immuno-oncology pharmacodynamic panel that has been used and published in a few clinical trials where they did phosphorylation status. So the final theme that comes out of most of these research based studies that are being done is that one size does not fit all. But the question that comes to my mind is how many things do you necessarily need to combine to get to a predictive biomarker that is useful, that is patient centric, and that perhaps is able to identify the right therapy for the right patient. What is your take on that, Phil?  Dr. Philippe Bedard: Yeah, that's a great question too. The challenge is it depends on the context in terms of what degree of positive predictive value do you need as well as the negative predictive value to drive clinical decisions. So I think in certain situations where you don't have other approved treatment options and with a therapy that is potentially low toxicity and low financial toxicity, then I think the bar is very high in terms of being able to really confidently identify that patients aren't going to benefit. I think the nuance and the challenge becomes when you move into earlier lines of therapy, or when you talk about combinations of agents, or trying to understand within the context of other available options, particularly with treatments that have significant side effect profiles as well as financial risks, then it becomes a much more nuanced question and you really need comparative studies to understand how it fits versus the existing treatment paradigm. So I'm not really answering your question with a specific number because I think it's hard to give you a number. Some of that we also need input from patients in terms of what kind of level of validation do you need and what kind of level of discrimination do you need in order to drive decisions that are meaningful for them. Dr. Rafeh Naqash: Definitely early days, as you pointed out. More and more work in this field will hopefully lead us in the direction that we all want to go in.  Now, going to a different aspect of this podcast, which is trying to understand the trajectories for both of you, Phil and Alberto. And as you mentioned, this project seemed to have started in 2015. So I'm guessing there's a history there between Princess Margaret and Vall d'Hebron. Could you highlight that a little bit? And then perhaps, Alberto, after that you could tell us a little bit about your career when you worked at Princess Margaret as a fellow and then now back at Vall d'Hebron. Phil, you as well. Dr. Philippe Bedard: So absolutely. We have a long history of collaborating with Vall d'Hebron in Barcelona. It's really a great cancer institution with a lot of like minded individuals. We have a formal partnership and we have a lot of informal links in terms of scientists and clinicians who we work with and who we collaborate with on early phase clinical trials, as well as through different investigator networks and other translational projects. So this was really how this collaboration came about and we were fortunate to have Alberto, who came to work with us for two years and brought this great idea of looking at this signature they had developed at Vall d'Hebron in their phase one group and applying it to a data set that we had through the INSPIRE clinical trial.  Dr. Rafeh Naqash: Sounds like a very successful academia-academic collaboration, which is very nice to see. So, Alberto, could you tell us a little bit about your career trajectory and how you ended up at Princess Margaret and then back at Vall d'Hebron and what you do currently? Dr. Alberto Hernando-Calvo: Yes. So I did my oncology residency at Vall d'Hebron in Barcelona, Spain. Then I decided to further specialize in early drug development as well as head and neck cancer oncology. So I decided to pursue a clinical research fellowship under the supervision of Phil Bedard, among others. And so we decided to further validate the signature that we had developed both in the cancer genomic lab at Vall d'Hebron Institute of Oncology and the phase one unit at Vall d'Hebron, and apply the signature that have been originally tested in patients receiving anti PD-1 or anti PDL-1 combinations in early phase clinical trials. In the phase 2 clinical trial of INSPIRE, where we also had ctDNA dynamics and allowed us to test both biomarkers and see that additive predictive power when we were using both. That was one of my research topics under the mentorship of Dr. Bedard and my fellowship at Princess Margaret. And this was one of the manuscripts describing all the findings of this collaboration between Vall d'Hebron and Princess Margaret Cancer Center. Dr. Rafeh Naqash: And then, Phil, if you could highlight some of the things that you've done over the course of your career and perhaps some advice for early career junior investigators and trainees.  Dr. Philippe Bedard: I finished my oncology, medical oncology training at the University of Toronto in 2008. And then I did a breast cancer fellowship in Brussels at Breast International Group. At the time, I was really intrigued because it was really kind of the early days of microarray and RNA signatures in terms of expressing signatures were being used as part of a clinical trial that BIG was running called the MINDACT Study. And so when I finished my fellowship, I came back to Princess Margaret, started on staff. I've been here now for 15 years. I was fortunate to work with the phase 1 group and kind of my career has sort of morphed in terms of early drug development as well as genomics. I've been involved with the American Association for Cancer Research project GENIE, where I'm the current chair. This is really an international data sharing project with panel based sequencing, which both Princess Margaret and Vall d'Hebron have contributed to. And I've been fortunate to work with a number of really talented early career investigators like Alberto, who spend time with us in our drug development program and launched transitional research projects that leverage some existing data sets at their own institutions and also bring together with different research groups at our institution to lead to publications like this one. Dr. Rafeh Naqash: Thank you so much. This was very exciting. Phil and Albert, thanks for joining us today and thank you for allowing us to discuss your interesting manuscript and hopefully we'll see more of this biomarker work from you guys in the near future, perhaps published in JCO Precision Oncology.   And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.     The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this podcast we have a chat with Shanna Whan, the founder of Sober in the Country. At AgWatchers, we are partial to a little tipple, but her charity is not anti-grog, it is about helping those who have a problem.  Shanna set up SITC to help people who have alcohol dependency problems in rural areas. In this chat, we go on a range of topics about alcohol dependency, from our favourite tipples to the difference between Scottish and Australian drinking culture. 

SITC is back with a new installment of Uncut and Unrated - extended "director's cuts" of some of our favorite episodes. FRATBOY F**KERY, our episode discussing a trio of "boys will be boys" blockbusters, returns to manspread its dick tentacles all over the airwaves. The original cut of this episode was released in April 2024 but the collective ethos of these misogynistic trash fires is now distinctly timely.  Tune in for previously unreleased deep cuts about Doug Kenney and the birth of The National Lampoon, another cringeworthy tale about Torie's adolescent pervy playacting, and much more.  Keep your eyes peeled and your ears open for all-new episodes including the first installment of our Director Retrospective series and our upcumming holiday special! --- Trigger warning: this episode discusses themes of sexual and verbal assault, rape, and body shaming. Welcome to the black hole of misogyny where "boys will be boys" and fratboy mentality reigned supreme to brainwash multiple generations.   Torie struggles to kill her darlings in the National Lampoon classic ANIMAL HOUSE (1978). Kim Cattrall is the only saving grace in the postulating butt boil that is PORKY'S (1981). Witness the birth of virtual assault and revenge porn in the generation-defining Y2K flick, AMERICAN PIE (1999).

Candel Therapeutics Chief Scientific Officer Dr. Francesca Barone joined Steve Darling from Proactive to share news the company is presenting at the Society for Immunotherapy of Cancer (SITC) conference. Barone, the company's Chief Scientific Officer shared details on CAN-3110, a first-in-class oncolytic viral therapy designed to selectively replicate within cancer cells. CAN-3110 is engineered to minimize effects on healthy cells while triggering a potent immune response within tumors, a promising innovation for treating difficult cancers like recurrent high-grade glioma and resistant melanoma. “Immunotherapy has transformed melanoma treatment, but many patients remain resistant,” Dr. Barone explained. Preclinical melanoma data shows CAN-3110 significantly reduces tumor burden while activating the immune system in cell models. The therapy's success in melanoma trials also hints at broader applications, with Dr. Barone citing potential future investigations into triple-negative breast cancer and sarcoma. With a strong safety profile, Candel Therapeutics is now considering targeted preclinical trials to assess CAN-3110's impact across additional challenging cancers. This novel therapeutic could offer new hope for patients with limited options, potentially transforming treatment landscapes for resistant tumor types. #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In recognition of Diwali, we are re-airing this episode, which features a conversation between Jennifer Brown and Mita Mallick, Head of Inclusion, Equity and Impact at Carta.  Jennifer and Mita discuss the importance of authentic and accurate representation of diverse cultures in the media. The conversation stemmed from a LinkedIn post by Mita about her reaction to the Diwali episode of And Just Like That, a revival of the HBO television series Sex and the City. Mita breaks down the episode, which was described in a Vogue article as a “messy tangle of misnomers and misappropriation.” Mita also discusses the exhaustion many people from marginalized communities feel, and what allies can do to help.

SITC is back with the long-awaited second installment of our horror series just in time for Halloween. Hot or not? You decide.  Body horror brings on the heat thanks to Jeff Goldblum's insectile sex symbol Seth Brundle in David Cronenberg's classic remake of THE FLY (1986). Julie Christie and Donald Sutherland prove graphic sex can have narrative value in Nicolas Roeg's enigmatic meditation on grief DON'T LOOK NOW (1973). Mia Farrow gets down with the devil and suffers the ultimate perversion of pregnancy in Roman Polanski's legendary ROSEMARY'S BABY (1968). 

Can AI offer humans genuine connection? Can AI be trusted? It is worth it to bang a bot?!? Tune in for SITC's most thought-provoking episode to date (in which Torie and Maggie disagree A LOT). Oscar Isaac's misogynist tech bro gets served by the scariest sexbot of all time in Alex Garland's masterfully character-driven psychological mindf**k, EX MACHINA (2014). A mustachioed Joaquin Phoenix turns up the heat with Manic Pixie Dreambot Samantha in Spike Jonzes's insufferably twee but undeniably poignant romantic classic HER (2013). John Malkovich charms as a wacky, well-endowed robot in Susan Seidelman's darling diamond in the rough, MAKING MR. RIGHT (1987). 

Quick note for our listeners. Apologies for minor technical issues, we recorded this "campfire episode" during a power outage on the first day of Mercury in Retrograde. Also, trigger warning for a brief mention of suicide in our coverage of the first film.  As we round out the summer, SITC is setting the scene on theme with three films featuring sex on the beach (the action, not the cocktail).  Torie and Maggie kick off with the Brooke Shields blockbuster and kissing cousin's classic THE BLUE LAGOON (1980). Maggie is thrilled with Torie's burgeoning bi-sexuality specific to the one Phoebe Cates in the atrocious Blue Lagoon ripoff, PARADISE (1982). Throuples and lizards run rampant on the island of Santorini in SUMMER LOVERS (1982) starring a young Daryl Hannah and Peter Gallagher. 

CATCH UP TIME! We went to get our fertility checked, fell in the love with the doctor, got proposed to (kinda), Mandi gets catcalled and Anna READS A BOOK! Of course it would not be SITC if we didn't lose track of conversation and end up in deep complex and hilariously unrelated topics. It's a long and classic episode from us today, hope you enjoy xxx PS - More episodes like this on Patreon x

Holy Balls it's SITC's one-year anniversary!!! To mark this momentous occasion, we're covering three (markedly more) momentous classics of lesbian Cinema.   Barren deserts (and wombs) get WET in the moving indie darling DESERT HEARTS (1985). Female pentathletes push past pain in PERSONAL BEST (1982). Torie and Maggie color-commentate  seven minutes of male gaze-infested f**king in the 2013 masterpiece, BLUE IS THE WARMEST COLOR. 

In this episode of JCO Article Insights, Rohit Singh interviews Dr. Ticiana Leal on the editorial, "Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade." TRANSCRIPT The guests' disclosures can be found in the transcript. Dr. Rohit Singh: Hello and welcome to JCO's Article Insights. I am your host Rohit Singh and today we will be discussing the JCO article, “Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade.” And we are joined by the senior author of the article, Dr. Ticiana Leal. Dr. Leal is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and she serves as director of Thoracic Medical Thoracic Oncology Medical Program and Multidisciplinary Thoracic Oncology Leader at the Winship Cancer Institute. She also served as a member of the Board of Directors at the Georgia Society of Clinical Oncology.  Dr. Leal, welcome to our podcast and thank you for joining us. Dr. Ticiana Leal: Thank you, Rohit. Thank you for this interesting opportunity to discuss our editorial. My co-authors and I are very glad to be here today. So, Dr. Jennifer Carlisle and Dr. Liu were co-authors with me on this editorial. Dr. Rohit Singh: It's a really good article. And just for our audiences, the article again, titled “Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade,” it discusses the challenges and the potential strategies for overcoming resistance to immune checkbox inhibitors in patients with non-small cell lung cancer. In this article, Dr. Leal and colleagues talk about the second line of drug when the patient developed disease progression while immunotherapy and they develop resistance and their definitions and what to do.  So, to Dr. Leal, can you please explain the mechanisms of primary and acquired resistance to immune check prohibitors in non-small cell lung cancer? I also saw in your article you proposed the definition of immunotherapy resistance in solid tumors, distinguishing between primary resistance and acquired resistance. So, if you can please share your thoughts and explain their mechanism. Dr. Ticiana Leal: So primary resistance and acquired resistance are related to tumor intrinsic and tumor extrinsic factors. And this is mainly clinically defined as of now according to previous response patterns and timing of occurrence, and these definitions can be heterogeneous, and we certainly think that biologically they can be very different. And it can be different according to prior therapy, whether patients got immunotherapy as PD-1, PD-L1 inhibitor alone or combination strategy with CTLA-4, or the combination with chemotherapy. But the patterns of resistance can be very different and can be based on defects and antigen presentation. It can also be due to tumor microenvironment immunosuppressive effects, and there are also additional inhibitory checkpoints that can be involved.  The definition in terms of when to call it primary or acquired resistance at this point has really been based on consensus guidelines by SITC, by Esmo, as well as our group Lung-MAP has developed clinical trials in this space. Specifically, through Lung-MAP, we've defined and incorporated the definition of acquired resistance as patients who have had prior exposure of 84 days or greater and then have had progression of their disease.  Dr. Rohit Singh: I can see why it is so challenging to come up with a standard definition for immune checkpoint resistance and I think incorporating these definitions and predictive biomarkers for clinical trial design is going to be more important going forward. Your article talks about CONTACT-01 study, so can you please discuss the CONTACT-01 study and how the shifting treatment paradigm in the first-time study impacted it and at the same time also discuss the potential implication of the differential outcome observed between the men and women in the CONTACT-01 study. Dr. Ticiana Leal: CONTACT-01 was a much-awaited study. The authors, Dr. Neal et al, looked at a very important question in the area of immunotherapy resistance. So, CONTACT-01 was a randomized phase three global study that investigated the combination of cabozantinib plus atezolizumab versus docetaxel in patients previously treated with chemotherapy and immunotherapy. And as background, cabozantinib is an inhibitor of multiple receptor tyrosine kinases including VEGFR-2, MET, RET and TAM family kinases. Preclinically, cabozantinib could lead to immuno permissive tumor microenvironment and so it was rational to combine it with a PD-1 inhibitor. In early results of a phase 1B expanded cohort of COSMIC-021 showed really promising results of this combination which led to the rationale of CONTACT-01. In this study, however, patients that were included had different prior treatment sequences. They could have had prior immunotherapy alone followed by chemo or the opposite, or they could have had prior immunotherapy and then upon progression gotten a combination of immunotherapy plus chemotherapy. That to say that immunotherapy rechallenge is something that people are doing in clinical practice given the unmet need and the desire to overcome immunotherapy resistance. But perhaps that also includes a more resistant population of patients, and these patients certainly could have had heterogeneous mechanisms of resistance which could have impacted these results.   The study did not meet the primary endpoint of overall survival. We saw a median overall survival of 10.7 months with the combination of atezo plus cabo and 10.5 months with docetaxel alone. In terms of the differences between sex that we saw in the CONTACT-01 study, just to go back in terms of the preclinical studies that have been done, there have been some preclinical studies that demonstrated that perhaps there may be some biological differences in models of different genders in mice. However, in the clinical setting, there have been, I think, contradicting results. A meta-analysis showed that perhaps women derive less benefit than men. Other studies have shown that perhaps women have more adverse events to immunotherapy. In this study specifically, only about 20% of the patients enrolled were women and the majority actually had non squamous histology. And we saw here less benefit for immunotherapy in women. But again, I think the numbers here are quite small. This is an exploratory analysis and I do think it highlights though the importance of making sure that we include populations and have higher rates of accrual, not only in women, but in other representative populations. In this study, only about 1% of the patients were black. Dr. Rohit Singh: Yeah. Thank you so much for highlighting those disparities. I think it's very important to make sure that we have proper representation of all the groups in our trials. I think based on just coming off the VEGF inhibitors, I think the Lung-MAP trial S1800A, showed a significant improvement in median OS with the combination of pembrolizumab and ramucirumab compared to standard of care. Do you envision any future commission therapies targeting the VEGF pathway with immune prohibitors in non-small cell lung cancer?  Dr. Ticiana Leal: I definitely think that targeting VEGF with multikinase TKIs based on the studies that we have seen, several now randomized phase 3 studies showing that this strategy is ineffective. So, this has been quite disappointing. But we've now seen the results of CONTACT-01, that we're just discussing here, but also other studies, including SAPPHIRE, which was also a randomized phase 3 that investigated nivolumab plus another VEGF multikinase TKI, sitravatinib. And then we also saw LEAP-008, which was a negative study investigating lenvatinib plus pembrolizumab. There still is a question though, whether you can target the VEGF pathway inhibition with a monoclonal antibody, so that's ramucirumab targeting VEGFR-2 plus ICI, and whether that can actually be an effective strategy. In our Lung-MAP trial, the S1800A, this study was a randomized phase 2. Here we used the definition of acquired resistance of patients receiving prior immune checkpoint inhibitor for a minimum of 84 days, and they were randomized to the combination of pembrolizumab plus ramucirumab versus investigator's choice of standard of care, which did include docetaxel, ramucirumab, docetaxel gemcitabine and methotrexate. This was a positive study. It led to significant improvement in median overall survival and there weren't any significant safety signals here. And we're waiting for another confirmatory study called the Pragmatica-Lung study.  Dr. Rohit Singh: Yeah, I did have one patient who raced through pembro, and I utilized this combination and was able to get some responses.  You mentioned Pragmatica-Lung trial. Can you provide more information about the ongoing Pragmatica-Lung trial and its potential impact on the treatment paradigm? Dr. Ticiana Leal: Yeah, the Pragmatica-Lung trial is an ongoing study, S2302. This is an effort that is ongoing. Dr. Karen Reckamp is the chair of this study. And this is a study that actually has a very, I think, modern study design. The term Pragmatica, this is an effort that is supported by the NCI to really propose a clinical trial design that is pragmatic to promote diversity and inclusion in clinical trials. The aim of this trial specifically is to validate what we saw in terms of overall survival in S1800A. So, in this study, patients with previously treated advanced non-small cell lung cancer are randomized 1:1 to the combination of pembrolizumab plus ramucirumab versus standard of care for patients previously treated with immunotherapy and chemotherapy for stage 4 recurrent non-small cell lung cancer. Primary endpoint here is overall survival. And I think this kind of highlights what we were talking about in terms of empowering investigators to treat patients in a clinical trial more so like a real-world setting. And I think this can be paradigm changing and decrease barriers to enrollment and also include now the real-world population that we see in clinical practice. Dr. Rohit Singh: Yeah, changing gears a little bit. I think your article also mentioned other agents that have been tested in ICI resistance settings, like lenvatinib-sitra. However, those trials results have been disappointing. What are the possible reasons behind those dose point results with multikinase inhibitors?  Dr. Ticiana Leal: We saw some really interesting, promising overall survival results with these combinations in phase two setting. In the phase 1B expansion with CONTACT-01, we saw prolonged overall survival that we thought would be promising enough to investigate in a phase 3. Ultimately, I don't know because there weren't any biomarkers that we could really tease out what was going on. Again, to highlight that both in LEAP-008 as well as CONTACT-01, there was no definition of immunotherapy resistance, which could have impacted, and we did choose the definition for SAPPHIRE, that patients had to have acquired resistance and immunotherapy had to be the most recent prior therapy. Ultimately, one potential reason for why these are not effective could be that this targeting with a multikinase TKI with multiple targets is ineffective, and you really have to target VEGF more precisely, which is the case here of ramucirumab, which targets VEGFR-2, and whether there are differences between a TKI and a monoclonal antibody may also impact the outcomes here.  Dr. Rohit Singh: You mentioned biomarkers. Do you think, are there any other potential biomarkers beyond PDL-1 or human mutation burden expression that can help us predict the response image checkpoint, especially in non-small cell lung cancer? Dr. Ticiana Leal: I think that's a great question. I definitely think that more effort needs to be dedicated, and of course, there are multiple efforts in this direction. One of the challenges, obviously, has been to obtain tissue to do this biomarker testing in clinical trials. When you look at CONTACT-01, they did PDL-1 expression, but this was all based on archival tissue and it was all based on standard of care, local testing. So, a lot of heterogeneity there, and certainly using PDL-1 at baseline from initial diagnosis for a second line trial may have significant flaws there. Ultimately, right now, for clinical practice, there isn't anything that's ready for prime time. But certainly, it sounds like, based on what we're seeing, that combining biomarkers is more likely to improve the accuracy. And I think a single biomarker alone is probably going to have insufficient predictive capacity. It'd be great to be able to better comprehensively characterize an individual's tumor, to individualize immunotherapy strategies in this relapse setting.  Dr. Rohit Singh: Yeah, definitely. We need more, better biomarkers. Coming to your point of heterogeneity, PD-L1. I myself had a patient, when we got PDL expressions from one site, they gave us one to 49%. However, for the testing, I sent the patient to a further lab at outset and PDL turned out to be 80%. But that was from a different site because of the bio sets only. Yeah, to your point, it's very heterogeneous and definitely we need to be more cautious interpreting those.  In that trial, in CONTACT-01, we have, through the patient who have oncogenetic lung cancer. Are there any plans to explore the role of immune checkpoint in oncogenetic lung cancer, especially like non-EGFR, non ALK? I know those are the ones that we have seen in multiple studies that don't respond but are other oncogenetic lung cancer is getting more and more target treatments coming out for non-small lung cancer? Dr. Ticiana Leal: Yeah. So, for patients with driver mutations, the paradigm has been well established that if there is a driver mutation, the patient should receive the appropriate targeted therapy. Immunotherapy as monotherapy has been ineffective in a lot of the patients with driver mutations beyond EGFR and ALK, certainly RET and HER2, ROS1, or other driver mutations that we believe that immunotherapy alone is ineffective. However, we are seeing some interesting ongoing clinical trials, or completed clinical trials investigating immunotherapy in patients with driver mutations. Going back to the EGFR population, we recently saw the results of HARMONi-A, which investigated ivonescimab, which is a bispecific antibody hitting PD-1, and VEGF, that in combination with chemotherapy, improved progression free survival in patients with EGFR mutated, non-squamous, non-small cell lung cancer with progression on prior TKI treatment. So, I think it is still an area of active investigation, and I do think that ongoing trials, perhaps with different PD-1, PD-L1 combination strategies such as bispecifics may be interesting but does require investigation. Dr. Rohit Singh: Yeah, definitely. It looks like combination therapy is going to be the most likely answer coming forward with more research, we're able to figure out the best possible treatment in this subgroup of patients. Considering the current challenges and ongoing research efforts, how do you see the field of non-small cell treatment evolving in coming years? Dr. Ticiana Leal: This is an interesting and important question. I think it's been really exciting to be working in thoracic oncology research. We have seen that these research efforts have led to advancement in the field. I think we need to continue to partner and collaborate with institutions, partner with industry, and also with patients and patient advocates to design clinical trials that are really going to focus on the needs of our patients in clinical trials. The gap in the second line and beyond after immunotherapy failure is a significant one. So, I do think that the challenges are to continue to develop biomarkers, to really understand who will benefit from immunotherapy strategies, who benefits from combinations, and most importantly, who does nothing. I think biomarkers are going to be something that we need to continue to incorporate in clinical trials, and I do think that there's a lot of room for hope and promise in the field. We've seen some interesting results with antibody drug conjugates and the combinations there may also be of interest. And then other important strategies, we're looking at T Cell engagers and different drugs with different mechanism of actions, including CAR T and vaccines. So beyond immune checkpoint inhibitors, I think we have different classes of drugs that may lead to different treatment strategies for patients in second line and beyond.  Dr. Rohit Singh: Yeah, certainly we have seen such extensive development in lung cancer. However, there's still a lot to be done as you just mentioned.  Thank you so much Dr. Leal for your time and great insights discussing your article with us. Dr. Ticiana Leal: Thank you. Dr. Rohit Singh: Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You'll find all ASCO shows at asco.org/podcast.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Dr. Leal Disclosures Consulting or Advisory Role Company name: Novocure Company name: Amgen Company name: Roche Company name: AstraZeneca Company name: Regeneron Company name: Novocure Company name: Takeda Company name: Jazz Pharmaceuticals Company name: Catalyst Pharmaceuticals Company name: Pfizer Company name: Janssen Company name: Genentech Company name: Novartis Company name: Sanofi Company name: BMS GmbH & Co. KG Company name: Abbvie Company name: OncoC4 Research Funding Company name: Pfizer Company name: Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses Company name: Regeneron Company name: Sanofi  

Welcome to Uncut and Unrated, SITC's version of the re-release. Instead of a straight up re-post of an older episode, we're giving you the podcast equivalent of a Director's Cut. SITC Uncut and Unrated includes everything we would have kept in - the digressions, the truly cringe-worthy anecdotes, and the content our paranoia convinced us would get us cancelled. LISTEN AT YOUR OWN RISK.  In the meantime, SITC is banking content like good little podcasters. Keep your ears open and your eyes peeled for all-new episodes dropping soon! We hope you enjoy the Uncut and Unrated version of Religious and Raunchy, one of our favorite episodes to date.  ---- Heresy alert! Please be advised this episode contains some serious sacrilege. Maggie drools over Gael Garcia Bernal in THE CRIME OF PADRE AMARO (2002). Torie gets a little (way) too excited about THE LAST TEMPTATION OF CHRIST (1988). Maggie gags on her sandwich during THE NAME OF THE ROSE (1986), whereas Torie finds an unexpected new crush. 

Cybersecurity leader Mike Isbitski explores the intricacies of cloud-native security and vulnerability management in today's technological landscape. With over 25 years of experience, he provides valuable insights into the challenges and complexities organizations face in securing ephemeral infrastructure and machine identities in the cloud. This episode also explores the cautious adoption of AI in cybersecurity, emphasizing the need for a balanced approach that maintains operational functionality while addressing evolving security concerns.Key Points with TimestampSecurity through Obscurity (00:00:00) - Mike discusses common security practices.Cloud-Native Technology Explained (00:01:30) - Unpacking the meaning of cloud-native tech.Evolving Vulnerability Management (00:03:38) - Insights on how vulnerability management has improved.AI in Cybersecurity (00:21:20) - Discussion on the slow but growing adoption of AI in cybersecurity.Challenges of Permissions and Identity (00:29:29) - The complexities of permissions in the cloud environment.Future Trends in Cybersecurity (00:34:11) - Predictions for changes and advancements in the cybersecurity landscape.About MichealMichael Isbitski is a former Gartner analyst, cybersecurity leader, and practitioner with more than 25 years of experience, specializing in application, cloud, and container security. Michael learned many hard lessons on the front lines of IT working on application security, vulnerability management, enterprise architecture, and systems engineering. He's guided countless organizations globally in their security initiatives as they support their businesses.Links Referenced:Sysdig: https://sysdig.com/Sysdig 2024 Cloud-Native Security and Usage Report: www.sysdig.com/SITC

UNAM recibió la acreditación internacional para la licenciatura de Química Farmacéutico Biológica La senadora Indira Kempis, se suma a las filas del PRIMás información en nuestro podcas

In this episode of SurgOnc Today®, Genevieve Boland, MD, PhD, Amanda Kirane, MD, and G. Paul Wright, MD, discuss breaking news and updates from the Society of Immunotherapy of Cancer (SITC) and Society of Melanoma Research (SMR) meetings.

Happy New Year and welcome back to Sonographers in the Cities! Lynn and Geselle catch up together after a long needed break and recap the year of 2023 and talk about what they hope for personally and professionally for 2024. Tune in to hear about what they are excited to share as they get transparent with their new goals and aspirations. Thank you for listening! Follow us on Instagram & find us on Facebook @sonographersinthecities

Our heroes attend their second Sin in the City Conference and share their new adventures as seasoned SitC pros! Visit our website: www.VanillawithaSideofKink.comInstagram: VanillawithaSideofKinkAlso, you can learn more about our Shibari Rope Bondage business at www.AllTiedUpSanDiego.comFetlife.com Group: Vanilla with a Side of Kink - The Podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is this week's round-up focus again. Most significantly, this week has seen the UK approval of a new indication for anastrozole in the prevention of breast cancer and a number of significant findings in the field of immunotherapy announced at SITC 2023. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Happy 2 year anniversary SITC family & Happy Medical Ultrasound Awareness month! Geselle & Lynn are back from their hiatus catching you up with what's been happening! We feature many of YOU in this episode and we're excited to be back! Tune in! Thank you for listening! Follow us on Instagram & find us on Facebook @sonographersinthecities

We are back to discuss the Sex and the City Movie with two Sex and the City experts! Joining us are Shortcomings' podcast hosts Samantha Bush and Christopher Lewis to get carried away and break down the movie that started it all. We dive into our tumultuous relationship with And Just Like That, the men of SATC (Team Mr. Big or Aiden Hive?), Florence Pugh giving Harry Goldenblatt in Oppenheimer, the hype surrounding the movie release, Kim Cattrall's birth chart, the 2008 Oprah interview sweeping our TikTok algorithms, Charlotte Poughkeepsie's her pants during Carrie's Mexi-coma, Louise from St. Louis is actually Carrie Bradshaw's ghost friend, Andre Leon Talley's iconic cameo, and our favorite looks from the Vogue Wedding shoot. Listen to Shortcomings https://podcasts.apple.com/us/podcast/shortcomings/id1575729786 Subscribe to the Shortcomings Patreon https://www.patreon.com/ShortcomingsPodcast Follow Sam on Instagram https://www.instagram.com/bravohistorian/ Follow Chris on Instagram https://www.instagram.com/clewis1219/ Listen to us on Apple: https://podcasts.apple.com/us/podcast/late-to-the-party-with-nikki-bri/id1593848890 Listen to us on Spotify: https://open.spotify.com/show/6Uk6XEk4IZIV34CiqvGQUa Listen to us on Google: https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy83MjBjMzM1OC9wb2RjYXN0L3Jzcw   Find us on Tik Tok https://www.tiktok.com/@thelatetothepartypod Find us on Twitter https://twitter.com/lttppod?s=11&t=N2TE0731pImO1eOG4T_wCQ Find us on Instagram https://instagram.com/thelatetothepartypod?igshid=NTc4MTIwNjQ2YQ==   (0:00) - Welcome Samantha and Christopher from Shortcomings Podcast! (5:20) - Our relationships with SITC (12:30) - Should the girls be single? (21:30) - The film's cultural impact on fashion (39:56) - Louise is a ghost theory (42:49) - The vogue shoot (53:14) - Final thoughts (58:03) - Where to find Samantha and Christopher A Hurrdat Media Production. Hurrdat Media is a digital media and commercial video production company based in Omaha, NE. Find more podcasts on the Hurrdat Media Network and learn more about our other services today on HurrdatMedia.com.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Eric Metaxas. Book- While Time Remains: A North Korean Defector's Search for Freedom in America by Yeonmi Park Yeonmi Park: While Time Remains https://youtu.be/kKQQU03Mr3Y Socrates in the City 72.8K subscribers 97,430 views Premiered Apr 25, 2023 North Korean defector Yeonmi Park joins Socrates in the City host Eric Metaxas to discuss her latest book WHILE TIME REMAINS. In this uniquely sobering SITC interview, Ms. Park details her early years: foraging for plants and eating bugs to stay alive in "Socialist Paradise," her family's involvement in the black market, escaping to China and being sold into slavery, and seeking freedom in South Korea by way of the Gobi Desert. The conversation then moves to Yeonmi's time studying at Columbia University in New York City. With insight from her time spent in a dictatorship filled with indoctrination, censorship, and mob rule, Park speaks to the current American landscape. The interview took place on March 30th, 2023 — 16 years to the day of her escape from North Korea in 2007 — at the Union League Club in New York City. To learn more about Socrates in the City, head to socratesinthecity.com. Yeonmi's Books "In Order To Live" and "While Time Remains" are available at socratesinthecity.com/shop/.   About the Book While Time Remains: A North Korean Defector's Search for Freedom in America by Yeonmi Park. February 14, 2023  NATIONAL BESTSELLER The North Korean defector, human rights advocate, and bestselling author of In Order to Live sounds the alarm on the culture wars, identity politics, and authoritarian tendencies tearing America apart. After defecting from North Korea, Yeonmi Park found liberty and freedom in America. But she also found a chilling crackdown on self-expression and thought that reminded her of the brutal regime she risked her life to escape. When she spoke out about the mass political indoctrination she saw around her in the United States, Park faced censorship and even death threats. In While Time Remains, Park highlights the dangerous hypocrisies, mob tactics, and authoritarian tendencies that speak in the name of wokeness and social justice. No one is spared in her eye-opening account, including the elites who claim to care for the poor and working classes but turn their backs on anyone who dares to think independently. Park arrived in America eight years ago with no preconceptions, no political aims, and no partisan agenda. With urgency and unique insight, the bestselling author and human rights activist reminds us of the fragility of freedom, and what we must do to preserve it. Audiobook available at-    https://www.amazon.com/While-Time-Remains-Freedom-America/dp/B0B4YZZ4HD/ref=tmm_aud_swatch_0?_encoding=UTF8&qid=&sr= --------------------------------------------------------------------  HELP ACU SPREAD THE WORD!  Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks. Forward this show to friends. Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime …And Many Other Podcast Aggregators and sites ACU on Twitter- https://twitter.com/AmerConU . Warning- Explicit and Violent video content.   Please help ACU by submitting your Show ideas. Email us at americanconservativeuniversity@americanconservativeuniversity.com Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks.   Endorsed Charities -------------------------------------------------------- Pre-Born! Saving babies and Souls. https://preborn.org/ OUR MISSION To glorify Jesus Christ by leading and equipping pregnancy clinics to save more babies and souls. WHAT WE DO Pre-Born! partners with life-affirming pregnancy clinics all across the nation. We are designed to strategically impact the abortion industry through the following initiatives:… -------------------------------------------------------- Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese -------------------------------------------------------- Food For the Poor https://foodforthepoor.org/ Help us serve the poorest of the poor Food For The Poor began in 1982 in Jamaica. Today, our interdenominational Christian ministry serves the poor in primarily 17 countries throughout the Caribbean and Latin America. Thanks to our faithful donors, we are able to provide food, housing, healthcare, education, fresh water, emergency relief, micro-enterprise solutions and much more. We are proud to have fed millions of people and provided more than 15.7 billion dollars in aid. Our faith inspires us to be an organization built on compassion, and motivated by love. Our mission is to bring relief to the poorest of the poor in the countries where we serve. We strive to reflect God's unconditional love. It's a sacrificial love that embraces all people regardless of race or religion. We believe that we can show His love by serving the “least of these” on this earth as Christ challenged us to do in Matthew 25. We pray that by God's grace, and with your support, we can continue to bring relief to the suffering and hope to the hopeless. -------------------------------------------------------- Disclaimer from ACU. We try to bring to our students and alumni the World's best Conservative thinkers. All views expressed belong solely to the author and not necessarily to ACU. In all issues and relations, we hope to follow the admonitions of Jesus Christ. While striving to expose, warn and contend with evil, we extend the love of God to all of his children.

In honor of the 25th anniversary and second season of And Just Like That, we discuss all things Sex and the City. We break down our favorite moments from the series, Carrie Bradshaw's influence on fashion, identifying as a Miranda, the movies, give Samantha Jones her flowers, the Che Diaz of it all, and why we will always love Sex and the City. Listen to us on Apple: https://podcasts.apple.com/us/podcast/late-to-the-party-with-nikki-bri/id1593848890 Listen to us on Spotify: https://open.spotify.com/show/6Uk6XEk4IZIV34CiqvGQUa Listen to us on Google: https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy83MjBjMzM1OC9wb2RjYXN0L3Jzcw   Find us on Tik Tok https://www.tiktok.com/@thelatetothepartypod Find us on Twitter https://twitter.com/lttppod?s=11&t=N2TE0731pImO1eOG4T_wCQ Find us on Instagram https://instagram.com/thelatetothepartypod?igshid=NTc4MTIwNjQ2YQ==   (0:00) – Identifying as Miranda and Carrie (7:20) – I think she's the anti-hero, which makes her immaculate (15:15) – Carrie Bradshaw's influence on fashion (20:40) – Carrie's role in the city (25:32) – The love interests (32:24) – We can't forget about Charlotte (29:14) – Our favorite seasons (46:06) – Thoughts on the SITC movies (54:04) – And Just Like That (1:04:50) – Predicting Samantha's cameo (1:10:30) – Favorite fits from the series (1:18:25) – We will ALWAYS love Sex and the City   A Hurrdat Media Production. Hurrdat Media is a digital media and commercial video production company based in Omaha, NE. Find more podcasts on the Hurrdat Media Network and learn more about our other services today on HurrdatMedia.com.

2023-6-15 10:01:41 episode date 2023-06-15

My house isn't clean enough!We all have ideas in our heads that stop us from crossing the street, literal or proverbial, and meeting our neighbor or familiar barista. However, as ambassadors for Christ we are called and empowered to know and be with our neighbors. Jamie shares what that looks like and how we can find encouragement while facing the challenges of life. 

WELCOME NEW LISTENERS! Get to know Geselle & Lynn in this episode as they reintroduce themselves, shares what SITC is all about, & why/how SITC was born! Thank you for listening! Follow us on Instagram & find us on Facebook @sonographersinthecities

In October 2022, the Society for Immunotherapy of Cancer released a checklist for running phase 3 cancer immunotherapy combination studies. SITC's aim with these guidelines is to maximize the value of these trials. In this episode, Fierce Pharma staff writer Angus Liu discusses the checklist with Dr. Michael Atkins, the first author. To learn more about topics in this episode: Moderna checks a few boxes in phase 3 mRNA flu shot trial, but misses on B strains and safety BD issues cybersecurity alert for hacking risk found in Alaris infusion pump software Apellis wins FDA approval for first geographic atrophy drug With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Monty Pal describes his recent study presented at SITC.

Happy Holidays! Geselle & Lynn celebrate the holidays in this episode by catching up with their work week & answers some tough questions that they received from their followers! 

28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.

On this episode, we're hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022... The post Updates in immunotherapy from SITC 2022 appeared first on VJOncology.

The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022... The post Updates in immunotherapy from SITC 2022 appeared first on VJOncology.

The lack of a “red wave” in the U.S. midterm elections sets up a “last gasp of old-fashioned, horse-trading politics” by lawmakers that could affect multiple pieces of life sciences legislation, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin details what's at stake for biopharma in Washington during the remaining weeks of 2022, and what's in store for life sciences in the next session of Congress. BioCentury's editors also discuss trends at this year's Society for Immunotherapy of Cancer (SITC) conference and the latest from the Distillery, BioCentury's summaries of top translational papers highlighting new targets and technologies with disease-modifying effects.

Chris Learn, Head of Cell and Gene Center of Excellent at Parexel, discusses his participation at the recent Clinical Research Virtual Summit hosted by the Society for Immunotherapy of Cancer, and the implications for clinical research.

When country woman Shanna Whan hit rock bottom in 2014 after a lifelong battle with alcohol addiction, she began a grassroots movement to tackle how we talk about booze in the bush

Site Centers (SITC) is a publicly-traded real estate investment trust investing in shipping centers. David Lukes, President and CEO, discusses how retailers and restaurants are adjusting to the shifting trends in consumers. He talks about the top investment ideas in retail REITs. He also goes over trends in restaurants such as how there is less indoor seating and carving out outdoor dining areas. Tune in to find out more.

Yes, this is the final episode of SAD IN THE CITY [insert crying emojis x 10].Thank you to every single person who has listened and followed us on this journey of creating this podcast. We love our SADDIES and to everyone who has ever written us an email, dent a DM, or commented on a video!While this is a goodbye, we hope you will find ways to connect with your city and continue the spirit of SITC where you may not have the answers (or the serotonin) but you don't give up and you keep trying.Love,Taylor and Brianna.

Getting sober in rural environments presents its own unique challenges. In this episode, Veronica interviews Shanna Whan founder of Sober in the Country a charity that helps people in rural places to stop drinking. Driven by desperation Shanna saw there was simply no support for people in rural Australia so she set about creating her own. Australian woman Shanna Whan is the pioneer of change in the bush when it comes to our love affair with booze. The founder and CEO behind national bush charity Sober in the Country spent 15,000 hours going against the grain to ''be the change'' and now her advocacy, raw and often irreverently funny conversations have seen the life-saving message that it's ''OK2SAYNO'' (to beers in the bush) go national and international. Shanna was recognised formally in 2021 by her peers and the public as a ProBono Australia winner in the ''Impact 25'' awards. Shanna Whan is a rural woman and in her own words a ''very unlikely'' national spokesperson for change when it comes to the complex subject of our great love affair with booze in the bush. The founder behind now nationally recognised brand and not-for-profit Sober in the Country Ltd (SITC) created the 'OK2SAYNO' campaign to ensure we are putting our mates and their health first. Far from being an anti-alcohol message; SITC is simply focused on advocacy, awareness, and ensuring those who choose to say 'no thanks' or 'not today' (no matter their reason) are supported fully. After almost losing her own life to alcohol addiction in 2015 and spending seven years of working tirelessly to support others she is now regularly referred to as a pioneer who cracked the lid on this yarn in the remote sector of Australia. Shan is not someone you'll ever find accepting labels like 'influencer,' or 'guru' spoken over her, though. She stands extremely firm on insisting she's just one of (too) many in the bush fighting a battle - sometimes for survival - without help, education, information, or even any appropriate support. So she said she simply decided to make it her life's work to change that. These days she is using her national media profile to boldly fight for us on a national level and to challenge our leaders to open their eyes, look west, and to see that for remote Australians, ''ISO'' is our reality.   To learn more, visit the show notes.

This episode was originally recorded as a LinkedIn Live, and features a conversation between Jennifer Brown and Mita Mallick, Head of Inclusion, Equity and Impact at Carta as they discuss the importance of authentic and accurate representation of diverse cultures in the media. The conversation stemmed from a LinkedIn post by Mita about her reaction to the Diwali episode of And Just Like That, a revival of the HBO television series Sex and the City. Mita breaks down the episode, which was described in a Vogue article as a “messy tangle of misnomers and misappropriation.” Mita also discusses the exhaustion that many people from marginalized communities are feeling, and what allies can do to help. To read the Vogue article about the episode, visit: https://www.vogue.in/fashion/content/sex-and-the-sari-investigating-the-diwali-episode-debacle-in-and-just-like-that

Pint #21 discusses scoops on the NFL recent COVID outbreak and how it affects the current playoff stretch as well as why some of the most successful CFB coaches have been unsuccessful in the NFL.  Toppings includes Peloton's cleaver #SITC ad, Affleck v. Garner and Spiderman - #NoWayHome.  Dogs of the Week picks look to bounce back for TCDs.  Mystery Scoop is Xmas centric - best gift you ever received and given in your entire life?!  Enjoy

The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. This week, we'll hear from two researchers who presented data at SITC.To listen to more podcasts from ASCO, visit asco.org/podcasts.

From Sushi and kombucha to face-eating squirrels this week's episode will have you laughing and perhaps nodding in agreement. The chair is cozy and the coffee is fresh! So we were wondering...Are you free for coffee?Music by:Golden Hour by Vlad Gluschenko https://soundcloud.com/vgl9

SITE Centers President & CEO David Lukes gives an overview of how economic reopening trends are impacting the outlook for SITE Centers and the rest of the REIT space: “It's surprisingly strong… the leasing environment right now is the best I've seen in decades.” The stock hit an all-time high this week.

The first episode of Scotch in the City's soon to be award winning podcast, we discuss the birth of SITC, where the idea came from and talk about our shady business dealings with NYC waiters.